Patch testing in systemic drug eruptions

Clinics in Dermatology

Volumn 15, Issue 4, 1997, Pages 479-484

  Bruynzeel, Derk P ^a   Maibach, Howard I ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ERUPTION; INCIDENCE; PATCH TEST; PATIENT CARE; PRIORITY JOURNAL; RELIABILITY; REVIEW; SENSITIZATION; SKIN MANIFESTATION;

EID: 0030850716     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00007-2     Document Type: Article

References (87)

1. Breathneck SM, Hinter H. Adverse drug reactions and the skin. Oxford: Blackwel Scientific Publishers 1992:3-13.
2. Pietzcker F, Kuner V. Anaphylaxie nach epicutanem Ampicillin-Test. Z Hautkr 1975;50:437-40.
3. Maucher OM. Anaphylaktische Reaktionen beim Epicutantest. Hautarzt 1972;23:139-40.
4. Schechter JF, Wilkinson RD, Del Carpio J. Anaphylaxis following the use of bacitracin ointment. Arch Dermatol 1984;120:909-11.
5. ®). Photodermatology 1987;4: 103-5.
6. Ikezawa Z, Kitamura K, Osawa J, et al. Photosensitivity to piroxicam is induced by sensitization to thimerosal and thiosalicylate. J Invest Dermatol 1992;98:918-22.
7. Imayama S, Fukuda H, Hori Y. Drug eruptions following treatment with prodrugs: A review of the reported cases in Japan from 1984-1989. J Dermatol 1991;18:277-80.
8. Dooms-Goossens A, Dooms M, van Lint L, et al. Skin sensitizing properties of arylalcanoic acids and their analogues. Contact Dermatitis 1979;5:324-8.
9. Bruynzeel DP, Van Ketel WG. Patch testing in drug eruptions. Semin Dermatol 1989;8:196-203.
10. Osawa J, Naito S, Aihara M, et al. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol 1990;17:235-9.
11. Wolkenstein P, Chosidow O, Fléchet M-L, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996;35:234-6.
12. Wakelin SH, Shaw S. The value of patch testing in suspected systemic drug allergy. In: Jadassohn Centenary Congress Abstractbook. London: European Society of Contact Dermatitis, 1996:62.
13. Van Ketel WG. Immunological investigations in patients with drug-induced skin eruptions. Br J Dermatol 1984;110: 112-3.
14. Camarasa JG, Serra-Baldrich E. Patch test in drug eruptions. In: First Congress of the European Society of Contact Dermatitis Abstractbook. Brussels: European Society of Contact Dermatitis, 1992:23.
15. Alanko K. Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis 1994;31:25-7.
16. Gonçalo M, Barros MA, Azenha A, The importance of photopatch testing in patients with photosensitive drug eruptions. In: Jadassohn Centenary Congress Abstractbook. London: European Society of Contact Dermatitis, 1996:15.
17. Terni T, Tagami H. Eczematous drug eruptions from carbamazepine: coexistence of contact and photocontact sensitivity. Contact Dermatitis 1989;20:260-4.
18. Ljunggren B, Bos G. A case of photosensitivity and contact allergy to systemic tricyclic drugs, with unusual features. Contact Dermatitis 1991;24:259-65.
19. Van Weelden H, Bolling HH, Baart de la Faille H, et al. Photosensitivity caused by chloroquine. Arch Dermatol 1982;118:290.
20. Suhonen R, Thioridazine photosensitivity. Contact Dermatitis 1976;2:179.
21. Kojima T, Hasegawa T, Ishida H, et al. Griseofulvin-induced photodermatitis. J Dermatol 1988;15:76-82.
22. Przybilla B, Ring J, Scwab U, et al. Photosensibilisierende Eigenschaften nichtsteroidaler Antirheumatika im Photopatch-Test. Hautarzt 1987;38:18-25.
23. Youn JI, Lee HG, Yeo UC, et al. Piroxicam photosensitivity associated with vesicular hand dermatitis. Clin Exp Dermatol 1993;18:52-4.
24. Figueiredo A, Fontes Reibeiro CA, Gonçalo S, et al. Piroxicam-induced photosensitivity. Contact Dermatitis 1987; 17:73-9.
25. 6). J Am Acad Dermatol 1996;35:304-5.
26. Ishibashi A, Hirano K, Nishiyama Y. Photosensitive dermatitis due to pyritinol. Arch Dermatol 1973;107:427-8.
27. Ljunggren B, Hindsen M, Isaksson M. Systemic quinine photosensitivity with photoepicutaneous cross-reactivity to quinidine. Contact Dermatitis 1992;26:1-4.
28. Neumann RA, Knobler RM, Lindemayr H. Tiaprofenic acid induced photosensitivity. Contact Dermatitis 1989; 20:270-3.
29. Calkin JM, Maibach HI. Delayed hypersensitivity drug reactions diagnosed by patch testing. Contact Dermatitis 1993;29:223-33.
30. Ruzicka T, Gerstmeier M, Przybilla B, et al. Allergy to local anesthetics: comparison of patch test with prick and intradermal test results. J Am Acad Dermatol 1987;16: 1202-8.
31. Van Joost T, Sillevis Smitt JH. Skin reactions to propranolol and cross sensitivity to β-adrenoreceptor blocking agents. Arch Dermatol 1981;117:600-1.
32. Romano A, Di Fonso M, Pietrantonio F, et al. Repeated patch testing in delayed hypersensitivity to beta-lactam antibiotics. Contact Dermatitis 1993;28:190.
33. Bruynzeel DP, Von Blomberg-van der Flier M, Scheper RJ, et al. Allergy for penicillin and the relevance of epicutaneous tests. Dermatologica 1985;171:429-34.
34. Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993;29:254-7.
35. Camarasa JG. Patch test diagnosis of exfoliative dermatitis due to carbamazepine. Contact Dermatitis 1985;12:49.
36. Prieto López C, Gamboa PM, Zugazaga Prieto M, et al. Study of various immunological parameters in the diagnosis of allergy to penicillin G and its derivatives. Allergol Immunpathol 1990;18:141-8.
37. Reynolds JEE (editor). Martindale. The extrapharmacoeia. London: Pharmaceutical Press, 1982:1764.
38. Smit AJ, Van der Laan S, De Monchy J, et al. Cutaneous reactions to captopril: predictive value of skin tests. Clin Allergy 1984;14:413-9.
39. Bonilla PAG, Rodriguez RG, Brito F, et al. Patch testing for allergy to beta-lactam antibiotics. Contact Dermatitis 1994; 31:319-34.
40. Romano A, Pietrantonio F, Di Fonso M, et al. Delayed hypersensitivity to cefuroxime. Contact Dermatitis 1992; 27:270-1.
41. Peters K. Delayed hypersensitivity to oral cimetidine. Contact Dermatitis 1986;15:190-1.
42. De Groot AC, Conemans J. Allergic urticarial rash from oral codeine. Contact Dermatitis 1986;14:209-14.
43. Felix RH, Comaish JS. The value of patch and other skin tests in drug eruptions. Lancet 1974;1:1018-9.
44. Saha M, Srinivas CR, Shenoi SD, et al. Sensitivity to topical medicaments among suspected cases of footwear dermatitis. Contact Dermatitis 1993;28:44-5.
45. Audicana M, Urrutia I, Echechipia S, et al. Sensitization to ephedrine in oral anticatarrhal drugs. Contact Dermatitis 1991;24:223.
46. Bircher AJ. Allergische Reaktionen vom Spättyp auf Heparine. Allergologie 1993;16:268-74.
47. Bircher AJ, Flückiger R, Buchner SA. Eczematous infiltrated plaques to subcutaneous heparin: a type IV allergic reaction. Br J Dermatol 1990;123:507-14.
48. De Cuyper C, Goeteyn M. Systemic contact dermatitis from subcutaneous hydromorphone. Contact Dermatitis 1992;27:220-3.
49. Quirce S, Parra F, Lázaro M, et al. Generalized dermatitis due to oral nystatin. Contact Dermatitis 1991;25:197-8.
50. Fernández de Corres L, Bernaola G, Lobera T, et al. Allergy from pyrazolone derivatives. Contact Dermatitis 1986;14:249-50.
51. Valsecchi R, Tornaghi A, Falgheri G, et al. Drug reaction from oxyphenbutazone. Contact Dermatitis 1983;9:419.
52. Landwehr AJ, Van Ketel WG. Delaued-type allergy to phenazone in a patient with erythema multiforme. Contact Dermatitis 1982;8:283-4.
53. De Boer EM, Bruynzeel DP. Allergy to pravastin. Contact Dermatitis 1994;30:238.
54. Vooys R, Van Ketel WG. Allergic drug eruption from pyrazolone compounds. Contact Dermatitis 1977;3:57-8.
55. Haneke EG, Körner E, Haneke E. Klinische Bedeutung positiver Penicillinreaktione. Dtsch Med Wochenchr 1980; 105:635-9.
56. Nilzén Å. Penicillin allergy. Acta Derm-Venereol 1956;36: 389-93.
57. Fernström ÅIB. Epicutaneous testing in penicillin-sensitivity. Acta Derm-Venereol 1956;36:394-9.
58. Fellner MJ. An immunologic study of selected penicillin reactions involving the skin. Arch Dermatol 1968;96:503-19.
59. Goday J, Aguirre A, Diaz-Pérez JL. A positive patch test in a pyrazinamide drug eruption. Contact Dermatitis 1990; 22:181-2.
60. Juste S, Blanco J, Garcés M, et al. Allergic dermatitis due to oral ranitidine. Contact Dermatitis 1992;27:339-40.
61. Romano A, Pietrantonio F, Di Fonso M, et al. Delayed hypersensitivity to stepronin: a case report. Contact Dermatitis 1993;29:166.
62. Camarasa JG, Serra-Baldrich E. Tetrazepam allergy detected by patch test. Contact Dermatitis 1990;22:246.
63. Bruynzeel I, Hebeda CL, Folkers E, et al. Cutaneous hypersensitivity reactions to vitamin K: 2 case reports and a review of the literature. Contact Dermatitis 1995;32:78-82.
64. Fischer AA. Systemic contact dermatitis. In: Rietchel RL, Fowler JF, editors. Contact Dermatitis. 4th ed. Baltimore: Williams & Wilkins, 1994:114-29.
65. Smeenk G. Uitwendige geneesmiddelen met inwendige toepassing; eczemateuze reacties. In: Van Joost T, Bruynzeel DP, editors. Huidafwijkingen door geneesmiddelen. Zeist: Glaxo, 1995:135-44.
66. Menné T, Maibach HI. Systemic contact-type dermatitis. In: Marzulli FN, Maibach HI, editors. Dermatotoxicology. New York: Hemisphere Publishing, 1991:453-72.
67. Fisher AA. Systemic eczematous "contact-type" dermatitis medicamentosa. Ann Allergy 1966;24:406-20.
68. Van Ketel WG. Systemic contact-type dermatitis by derivatives of adamantane? Dermatosen 1988;36:23-4.
69. Van den Berg WHHW, Van Ketel WG. Contactallergie voor ethyleendiamine. Ned Tijdschr Geneeskd 1983;127: 1801-2.
70. Maibach HI. Oral substitution in patients sensitized by transdermal clonidine treatment. Contact Dermatitis 1987; 16-8.
71. Stingeni L, Caraffini S, Assolve D, et al. Erythema-multiforme-like contact dermatitis from budesonide. Contact Dermatitis 1996;34:154-5.
72. Redondo VF, Casas L, Taboada M, et al. Systemic contact dermatitis from erythromycin. Contact Dermatitis 1994; 30:43-4.
73. Grob JJ, Mege JL, Follana J, et al. Skin necrosis after injection of aminosides. Dermatologica 1990;180:258-62.
74. Ekelund A-G, Möller H. Oral provocation in eczematous contact allergy to neomycin and hydroxy-quinolines. Arch Derm Venereol 1969;49:422-6.
75. Van Dijke CPH, Veerman FR, Haverkamp HCH. Anaphylactic reactions to ketoconazole. Br Med J 1983;287:1673.
76. Curley RK, Macfarlane AW, Kong CM. Contact sensitivity to the amide anesthetics lidocaine, prilocaine, and mepivacaine. Arch Dermatol 1986;122:924-6.
77. Nissenkorn I, Herrod H, Soloway MS. Side effects associated with intravesical mitomycin C. J Urol 1981;126:596-7.
78. Christensen OB. Two cases of delayed hypersensitivity to mitomycin C following intravesicular chemotherapy of superficial bladder cancer. Contact Dermatitis 1990/23: 263.
79. De Groot AC, Conemans J. Contact allergy from mitomycin C after intravesicular instillation. Contact Dermatitis 1990;23:263-4.
80. Lechner T, Grytzmann B, Bäurle G, Hämatogenes allergisches Kontaktekzem nach oraler Gabe von Nystatin. Mykosen 1987;30:143-6.
81. Shmunes E. Allergic dermatitis to benzyl alcohol in an injectable solution. Arch Dermatol 1984;120:1200-1.
82. Brown JL. Incomplete labeling of pharmaceuticals: a list of "inactive" ingredients. New Eng J Med 1983;309:439-41.
83. Kolly M, Pécoud A, Frei PC. Additives contained in drug formulations most frequently prescribed in Switzerland. Ann Allergy 1989;62:21-5.
84. Pollock I, Young E, Stoneham M, et al. Survey of colourings and preservatives in drugs. Br Med J 1989;299:649-51.
85. Houwerzijl J, De Gast D, Nater J, et al. Lymphocytic-stimulation tests and patch tests in carbamazepine hypersensitivity. Clin Exp Immunol 1977;29:272-7.
86. De Groot AC. Patch testing. 2nd ed. Amsterdam: Elsevier 1994, 13-281.
87. Van Ketel WG. Patch testing in penicillin allergy. Contact Dermatitis 1975;1:253-4.